Achieve Life Sciences Inc. (ACHV) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12% realized swing band)
FRED Regime × Technicals: 76% of 52W Range • RSI-14 at 46.4 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ACHV currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.45) and Max Pain ($7.55) forces dealer call-delta covering toward $9.07.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Achieve Life Sciences Inc. (ACHV) surged +4.96% to $7.19, trading at 76% of its 52-week range ($2.62 – $8.64). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year Among the participants new to cytisin
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACHV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACHV. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Achieve Life Sciences Inc. (ACHV) ranks #504 by composite RQD confidence (44/100, grade D) and #394 by equity capitalization ($739.9M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with ACHV at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACHV
ACTIVE
Achieve Life Sciences Inc. | D | 44/100 | — | — | -35.0% | +4.96% | $739.9M | Benchmark Subject |
| MYGN Myriad Genetics Inc. | D- | 39/100 | — | 69.9% | -35.0% | +0.60% | $638.0M | /mygn-vs-achv → |
| QDEL QuidelOrtho Corporation | E | 30/100 | — | — | -35.0% | -1.78% | $943.6M | /qdel-vs-achv → |
| NNNN Anbio Biotechnology (Class A) | D | 45/100 | 83.6x | 87.2% | 17.0% | -3.12% | $535.3M | /nnnn-vs-achv → |
| TKNO Alpha Teknova Inc. | D | 44/100 | — | 33.2% | -21.3% | +2.93% | $499.2M | /tkno-vs-achv → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Achieve Life Sciences Inc. (ACHV) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$54.6M, operating cash flow of -$49.5M, and free cash flow of -$49.5M (-66.2% YoY). On the balance sheet, ACHV closed FY2025 with $41.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$54.6M | -$49.5M | -$49.5M | $41.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$39.8M | -$29.8M | -$29.8M | $38.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$29.8M | -$24.5M | -$24.5M | — | — |
As of 2026-11-01, Achieve Life Sciences Inc. (NASDAQ: ACHV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $7.19 (+4.96% 1D, market cap $739.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ACHV ranks #504 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ACHV carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MYGN (Myriad Genetics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M) and QDEL (QuidelOrtho Corporation) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $943.6M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
Per ACHV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000949858), Achieve Life Sciences Inc. generated $0 in revenue, -$54.6M in net income, and -$49.5M in free cash flow against $41.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ACHV last traded at $7.19 (+4.96% on volume of 1,375,122 shares), positioning the stock -3.49% below its 50-day simple moving average ($7.45) and +27.48% above its 200-day simple moving average ($5.64). Across its 52-week range of $2.62 to $8.64, ACHV sits at the 75.9% percentile with a 14-day RSI of 46.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($6.33 to $8.05).
Why ACHV Stock surged +4.96% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.